CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Tarceva +1 moredrug
Likely dose
Tarceva 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00888511
NCT00888511Phase 2Completed
CompareCT.gov

Concomitant Tarceva® and Irradiation in Patients in Local-regionally Advanced Non-small Cell Lung Cancer. A Phase II Study

Olfred Hansen·interventional·Posted Apr 27, 2009·Updated Nov 27, 2020

In Brief

A Phase 2 clinical trial evaluating Tarceva and Radiotherapy for Non-small Cell Lung Cancer. Completed, enrolled 15 participants across 7 sites.

Detailed Summary

The trial is a phase II study of daily Tarceva combined with definitive radiotherapy in inoperable locally advanced non small cell lung cancer (stage IIB-IIIB). The objective of the phase II trial is to examine Tarceva concomitant with curatively intended irradiation 66 Gy (2 Gy x 33 F, 5 F per week).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesDenmark
CollaboratorsOdense University Hospital, Copenhagen University Hospital at Herlev, Rigshospitalet, Denmark, Aalborg University Hospital, Aarhus University Hospital, Naestved Hospital

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 27, 2009
Enrollment StartMay 1, 2009
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 17.2 years ago

Interventions

Tarcevadrug

Tarceva 150 mg/day

Radiotherapyradiation

66 Gy/33 F/5 F per week for 5 weeks